{
  "case_id": "MN19-31293",
  "year": 2019,
  "patient_info": {
    "age_range": "41 to 50",
    "gender": "Female"
  },
  "diagnosis": "Immuno Disorders",
  "secondary_conditions": [],
  "complications": [],
  "symptoms": [],
  "treatment_category": "Pharmacy",
  "treatment_subcategory": "Hormones",
  "treatments_requested": [
    {
      "name": "H.P. Acthar Gel",
      "drug_type": "other",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    }
  ],
  "treatments_tried_but_failed": [],
  "treatments_tried_and_worked": [],
  "treatments_not_tried": [
    {
      "name": "Rituximab",
      "drug_type": "other",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": "Recommended for refractory non-renal disease"
    }
  ],
  "is_denial_upheld": true,
  "issues_considered": [
    "medical_necessity"
  ],
  "other_issues": null,
  "guidelines_support": false,
  "guidelines_not_support": true,
  "guidelines_details": "Guidelines do not support the use of Acthar Gel for non-renal systemic lupus erythematosus (SLE) or SLE-APS.",
  "soc_support": false,
  "soc_not_support": true,
  "soc_details": "Rituximab recommended for refractory non-renal disease.",
  "study_support": true,
  "study_details": [
    {
      "study_name": "Repository Corticotropin Injection (RCI) Study",
      "study_authors": "Not specified",
      "key_findings": "RCI has anti-inflammatory and immune-modulatory effects, used as late-line therapy in rheumatologic diseases. No exclusive studies on SLE-APS."
    }
  ],
  "key_questions": [
    "medical_necessity"
  ],
  "expedited": true,
  "rationale": "The requested medication is not medically necessary for the treatment of the patient\u2019s condition. Guidelines recommend rituximab for refractory non-renal disease.",
  "reviewer_credentials": "Board certified in internal medicine with subspecialty certifications in allergy and immunology and rheumatology."
}